A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dose, Dose-escalation Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 After Oral Administration in Healthy Male Subjects, Phase I Study

Trial Profile

A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dose, Dose-escalation Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 After Oral Administration in Healthy Male Subjects, Phase I Study

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2014

At a glance

  • Drugs CJ 12406 (Primary)
  • Indications Helicobacter pylori infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors CJ Cheiljedang Corp.
  • Most Recent Events

    • 01 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top